Skip to main content

FantasySpin and FastDraft Announce Merger to Create the Ultimate Fantasy Sports Platform

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — FantasySpin, a premier Daily Fantasy Sports (DFS) operator, and FastDraft, the rapidly growing Best Ball platform, today announced a corporate merger. The strategic combination will create a fantasy sports powerhouse offering sports fans an unparalleled, all-encompassing fantasy experience. FantasySpin and FastDraft booked over $1M in contest entries in the first year. The stage is now set for massive 2026/2027 growth as FantasySpin contests will be available to an expanded population of 330 million people across 38 U.S. states and Canada. DFS Innovation Leader FantasySpin, renowned for its groundbreaking contributions to the Daily Fantasy Sports (DFS) industry, strengthens its market position with this merger. The company’s patented DFS products gamify the process of building fantasy lineups...

Continue reading

Sienna Continues Platform Growth

MARKHAM, Ontario, May 04, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company“) (TSX: SIA) announced today that it has entered into two purchase agreements to acquire a retirement residence in the Greater Ottawa Area and a long-term care community in the Greater Toronto Area (“GTA”) for a combined investment of approximately $109 million. On May 1, 2026, the Company entered into a purchase agreement to acquire Ballycliffe, a 224-bed, newly built long-term care community in Ajax, Ontario, located within the Greater Toronto Area. The gross purchase price for the property, which opened in Q3 2025 and includes all rights to the asset’s 25-year construction funding subsidy, is approximately $68.3 million, or $305,000 per bed, with an initial Investment Yield of approximately 6.75%....

Continue reading

Quantum X Labs Files U.S. Patent Application for High Precision Quantum Atomic Clock for Potential Use in the Aerospace & Defense Industries

Tel Aviv, Israel, May 04, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (Nasdaq: QXL) (“QXL” or the “Company”), an advanced technologies company (formerly known as Viewbix Inc. (Nasdaq: VBIX)), announced today the filing of a U.S. patent application covering a novel compact atomic clock. By interrogating rubidium atoms with correlated optical fields the system suppresses existing atom clocks. The technology covered by the patent application is based on a compact atomic clock architecture using Ramsey coherent population trapping. High-precision atomic clocks are essential for the aerospace and defense industries for applications such as satellite navigation, secure communication networks, radar synchronization, autonomous platforms and other advanced defense technologies. Other industries that might need that level of timing synchronization...

Continue reading

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases. China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. Strengthened leadership team in U.S., coupled with China operating presence to support future global growth.SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced the closing of its acquisition of Cullgen Inc....

Continue reading

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30...

Continue reading

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

COPENHAGEN, Denmark, May 4, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. To join the webcast, please click on this link. The webcast recording will be available...

Continue reading

Reliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA’s Biotech Division

Transaction Expands EZRA International Group’s Biotech Division, LifeSci Global, Into Late-Stage Radiopharmaceutical Imaging Initial Neuroblastoma Opportunity of Approximately $250 Million, with Additional Potential Billion-Dollar Expansion Markets and Priority Review Voucher Upside LAKEWOOD, N.J., May 04, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced that LifeSci Global Group LLC (“LifeSci Global”), the biotech arm of EZRA International Group, has completed a strategic investment in Innervate Radiopharmaceuticals, a developer of positron emission tomography (PET) imaging and therapeutic radiopharmaceuticals focused initially on neuroblastoma and broader future applications in cardiovascular and neurodegenerative disease. This investment reflects...

Continue reading

Bombardier Announces Launch of US$500,000,000 New Issuance of Senior Notes due 2035 to retire Senior Notes due 2029

MONTREAL, May 04, 2026 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500,000,000 aggregate principal amount of new Senior Notes due 2035 (the “New Notes”). Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the repayment and/or retirement of outstanding indebtedness, including the redemption of all of its outstanding 7.50% Senior Notes due 2029 (the “2029 Notes”, and such redemption, the “Conditional 2029 Notes Redemption”), and (ii) to pay accrued interest and related fees and expenses. As of the date hereof, there is US$750,000,000 aggregate principal amount outstanding of the 2029 Notes. Consummation of the offering of the New Notes and the Conditional 2029 Notes Redemption are subject to market and other conditions,...

Continue reading

Bombardier Announces Conditional Notice of Redemption for All Outstanding 7.50% Senior Notes due 2029

MONTREAL, May 04, 2026 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a conditional notice of redemption (the “Notice of Redemption”) for all of its outstanding 7.50% Senior Notes due 2029, in an aggregate principal amount of US$750,000,000 (the “2029 Notes”). As set forth in the Notice of Redemption, the redemption date is May 19, 2026, and the redemption price for the 2029 Notes is 103.750% of the principal amount redeemed, plus accrued and unpaid interest. The redemption of the 2029 Notes is subject to and conditioned upon Bombardier completing a new offering of debt securities in the aggregate principal amount of not less than US$500,000,000 before the May 19, 2026 redemption date (the “New Notes”); however, Bombardier may delay or waive this condition in its sole and absolute discretion....

Continue reading

Slide Insurance Expands Homeowners Coverage to California

Launches excess and surplus (E&S) lines program to address shrinking insurance market, leveraging recognized expertise as a leading coastal specialty insurer TAMPA, Fla., May 04, 2026 (GLOBE NEWSWIRE) — Slide Insurance Holdings, Inc. (“Slide” or the “Company”) (NASDAQ: SLDE) today announced its expansion into California, launching a residential property excess and surplus (E&S) lines program and writing its first policy in the state. Slide’s entry into California comes at a critical time for the state, as several major carriers have reduced their presence or exited entirely, leaving property owners facing canceled policies and limited coverage options. With Slide’s arrival, California homeowners and landlords will benefit from the Company’s expertise in underwriting catastrophe-exposed markets, supported by strong capitalization...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.